CORT
NASDAQ · Pharmaceuticals
Corcept Therapeutics Inc
$79.71
-0.20 (-0.25%)
Financial Highlights (FY 2026)
Revenue
681.22M
Net Income
89.16M
Gross Margin
98.3%
Profit Margin
13.1%
Rev Growth
+23.7%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 98.3% | 98.3% | 41.7% | 41.7% |
| Operating Margin | 5.9% | 5.3% | 27.9% | 25.4% |
| Profit Margin | 13.1% | 12.4% | 22.8% | 19.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 681.22M | 550.53M | 785.70M | 815.78M |
| Gross Profit | 669.64M | 541.17M | 328.03M | 340.58M |
| Operating Income | 40.06M | 29.13M | 219.32M | 207.21M |
| Net Income | 89.16M | 64.85M | 178.89M | 159.66M |
| Gross Margin | 98.3% | 98.3% | 41.7% | 41.7% |
| Operating Margin | 5.9% | 5.3% | 27.9% | 25.4% |
| Profit Margin | 13.1% | 12.4% | 22.8% | 19.6% |
| Rev Growth | +23.7% | +23.7% | +17.7% | +19.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 406.47M | 449.40M |
| Total Equity | — | — | 2.76B | 2.61B |
| D/E Ratio | — | — | 0.15 | 0.17 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 41.10M | 31.56M | 255.84M | 269.33M |
| Free Cash Flow | — | — | 116.31M | 99.81M |